Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes

Previous data showed that in the phase 3 JAVELIN Bladder 100 trial, patients with advanced urothelial carcinoma who had not progressed following first-line platinum-based chemotherapy experienced significantly improved overall and progression-free survival with Bavencio (avelumab) plus best supportive care versus best supportive care alone, according to the Journal of Clinical Oncology.

Based on these outcomes, investigators conducted an exploratory analysis to assess outcomes based on the presence or absence of diabetes mellitus in patients. In an interview with CURE, Dr. Petros Grivas broke down these trial results, detailing that Bavencio showed clinical benefit and a consistent safety profile regardless of diabetes status.

Grivas is the clinical director of the Genitourinary Cancers Program and a professor in the Clinical Research Division at Fred Hutch Cancer Center, in Seattle; he also serves as a professor in the Division of Hematology and Oncology, at the University of Washington School of Medicine.

Transcript:

[Data] from the JAVELIN Bladder 100 phase 3 trial [showed] that switch maintenance with Bavencio — an anti-PD-1 immunotherapy —[demonstrated] significant overall and progression-free survival with Bavencio switch maintenance. We have conducted many studies since then, and the landscape continues to change. Obviously, we have practice-changing data [since then], so the landscape has changed significantly in the last few years.

A sub-study, [also called an] exploratory analysis, was conducted specifically looking at patients with and without diabetes mellitus. The key takeaway was that the benefit with Bavencio switch maintenance in the context of the JAVELIN Bladder 100 trial was independent of the presence of diabetes. Both patients with and without diabetes mellitus benefited from Bavencio switch maintenance therapy after responding to or achieving stable disease with platinum-based chemotherapy.

Transcript has been edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.